• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025

    7/2/25 7:30:00 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care
    Get the next $BBNX alert in real time by email

    IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after the financial markets close on Tuesday, July 29, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time).

    The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BIc649100069fd4629a4ed5bf4826b8acb.

    About Beta Bionics

    Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

    Investor Relations:

    Blake Beber

    Head of Investor Relations

    [email protected]

    Media and Public Relations:

    Karen Hynes

    Vice President of Marketing

    [email protected]

    Source: Beta Bionics, Inc.



    Primary Logo

    Get the next $BBNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBNX

    DatePrice TargetRatingAnalyst
    6/16/2025$26.00Buy
    Truist
    6/12/2025$30.00Buy
    Lake Street
    5/30/2025$16.00Neutral
    Goldman
    5/30/2025$20.00Outperform
    Wolfe Research
    2/24/2025Buy
    BofA Securities
    2/24/2025$30.00Buy
    Lake Street
    2/24/2025$25.00Buy
    Stifel
    2/24/2025$26.00Overweight
    Piper Sandler
    More analyst ratings

    $BBNX
    SEC Filings

    See more
    • Beta Bionics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Beta Bionics, Inc. (0001674632) (Filer)

      6/23/25 7:31:31 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Beta Bionics Inc.

      SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)

      5/15/25 4:30:19 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Beta Bionics Inc.

      SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)

      5/15/25 8:15:33 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care